← Back to Search

Monoclonal Antibodies

Bimekizumab for Plaque Psoriasis (BE BRIGHT Trial)

Phase 3

Waitlist Available

Research Sponsored by UCB Biopharma SRL

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from baseline to safety follow up 2 (up to week 220)

Awards & highlights

BE BRIGHT Trial Summary

This trial will study the long-term effects of a medication called bimekizumab on adults with moderate to severe plaque psoriasis.

Eligible Conditions

Moderate to Severe Chronic Plaque Psoriasis
Plaque Psoriasis

BE BRIGHT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from baseline to safety follow up 2 (up to week 220)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from baseline to safety follow up 2 (up to week 220)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to safety follow up 2 (up to week 220) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Treatment Emergent Adverse Events (TEAEs) adjusted by duration of subject exposure to Investigational Medicinal Product (IMP)

Secondary outcome measures

Investigator´s Global Assessment (IGA) 0/1 response at Week 144

Number of Serious Adverse Events (SAEs) adjusted by duration of subject exposure to IMP

Number of TEAEs leading to withdrawal adjusted by duration of subject exposure to IMP

+1 more

BE BRIGHT Trial Design

2Treatment groups

Experimental Treatment

Group I: Bimekizumab dose regimen 2Experimental Treatment1 Intervention

Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label). Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2. Intervention Name: Bimekizumab

Group II: Bimekizumab dose regimen 1Experimental Treatment1 Intervention

Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48) Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks. Intervention Name: Bimekizumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bimekizumab

2018

Completed Phase 3

~6510

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor

101 Previous Clinical Trials

20,081 Total Patients Enrolled

UCB CaresStudy Director001 844 599 2273

205 Previous Clinical Trials

43,608 Total Patients Enrolled

Media Library

Bimekizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03598790 — Phase 3

Plaque Psoriasis Research Study Groups: Bimekizumab dose regimen 1, Bimekizumab dose regimen 2

Plaque Psoriasis Clinical Trial 2023: Bimekizumab Highlights & Side Effects. Trial Name: NCT03598790 — Phase 3

Bimekizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03598790 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the precedent for Bimekizumab usage?

"At the moment, there are 8 different ongoing clinical trials for Bimekizumab. 7 of those trials are in the final Phase 3. Most of the research for Bimekizumab is conducted in Phillip, Oregon; however, there are 1,025 total locations running clinical trials for this medication."

Answered by AI

Could you please explain the possible adverse effects of Bimekizumab?

"We believe that Bimekizumab is safe to use because it has passed multiple safety trials and there is some evidence that it is effective."

Answered by AI

Has a similar study to this one been conducted before?

"UCB Biopharma SRL sponsored the first trial for Bimekizumab in 2018. 743 patients were involved in the Phase 3 study which completed its drug approval stage that year. Currently, there are 8 active trials involving Bimekizumab across 26 countries and 120 cities."

Answered by AI

Is this study conducted in many different hospitals across America?

"74 trial sites are currently operational. Some are located in major cities like Oakville, Montréal and Richmond Hill, while others are based in more rural areas. To cut down on travel, it is recommended that patients select the site closest to them."

Answered by AI

Can people with the qualifying medical conditions participate in this trial today?

"No, this particular study is not looking for new patients at the moment according to the most recent update on clinicaltrials.gov. Although this trial isn't taking any more participants, there are still 189 other open trials that are."

Answered by AI